Dermatology
Bullous Pemphigoid (BP): Exploring New Frontiers
Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.
MD, FAAD, MA, BMBCh, DSc
Dédée Murrell +3 more
Related resources
The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD
Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU
Learning objectives
- • Describe the heterogenous clinical presentations, disease burden, and diagnosis of bullous pemphigoid (BP)
- • Highlight current understanding of BP pathophysiology and the critical role of autoimmunity and type 2 inflammation in both clinical signs and itch
- • Discuss unmet needs from a clinical management perspective and how targeted therapies may address them
Description
In this ADVENT symposium at the 2024 EADV meeting, Professor Dedee Murrell is joined by colleagues Dr. Donna Culton, Professor Joost Meijer and Professor Enno Schmidt to provide updates for HCPs who treat patients with bullous pemphigoid (BP), a chronic relapsing autoimmune inflammatory skin disease. There is a need to better understand the complex mechanisms, involving autoimmunity and type 2 inflammation, which give rise to lesions, itch, and pain, the burdensome hallmark symptoms of BP. Current management guidelines, treatment challenges, and potential opportunities with targeted therapies will also be discussed.
Tags
MAT-GLB-2406804 - 1.0 -10/2024
About these experts
